They evaluated the results of Ivermectin tested in 24 randomized controlled clinical trials involving 3,406 participants, assessing its efficacy in reducing mortality and secondary outcomes in people with, or at high risk of COVID-19.
They found that Ivermectin's antiviral and anti-inflammatory properties were beneficial and that it reduced the risk of death compared with no ivermectin in COVID-19 patients by an average of 62% (risk ratio .38%).
They also found that ivermectin prophylaxis reduced COVID-19 infection by an average of 86% (95% confidence interval 79%–91%).
"Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin," they concluded.
"Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally."
Of 63 controlled studies, the data shows a 69% improvement among patients for early treatment.
The 63 trials involved 613 scientists and 26,398 patients in 31 randomized controlled trials.
Summaries of other studies include 86% improvement in 14 prophylaxis trials, 69% improvement in 27 early treatment trials, 40% improvement in 22 late treatment trials, and 60% improvement in 31 randomized controlled trials.
Despite this, the NIH maintains that "no clinical trials have reported a clinical benefit for ivermectin in patients with these viruses."